REG - Cambridge Cognition - Contract Win

Cambridge Cognition HoldingsAnnouncement

10/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250410:nRSJ3928Ea&default-theme=true

RNS Number : 3928E  Cambridge Cognition Holdings PLC  10 April 2025

10(th) April 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Contract Win

 Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune
Disease Trial

Cambridge Cognition (AIM: COG), the brain health software group specialising
in digital products to advance clinical research and patient treatment, has
been selected by a major pharmaceutical company to provide digital cognitive
assessments for a large Phase 3 autoimmune disease clinical trial. The initial
contract, starting in 2025 and running through to 2031, is valued at
approximately £1 million.  The Company has previously provided services to
this customer, and this represents repeat business with this global company.

Autoimmune diseases represent a significant unmet medical need where both
physical and cognitive symptoms play a critical role in disease burden. Many
patients, with persistent symptoms like fatigue, joint pain, and cognitive
impairment (often referred to as "brain fog") remain underdiagnosed and
untreated and this impacts quality of life(1). The decision by our client to
use CANTAB®'s cognitive assessments in an autoimmune disease trial reflects
an expanding recognition of the multifaceted nature of autoimmune disorders
and the critical importance of considering the impact on the central nervous
system.

Cambridge Cognition was selected by this existing customer due to our
scientifically validated, proprietary cognitive assessments and our proven
ability to deliver digital cognitive testing solutions on a global scale.
Supported by an experienced clinical project management team, CANTAB® will be
deployed in 16 countries and 23 languages across 245 trial sites to support
this study.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"We view this repeat business from an existing customer as a strong
endorsement of our product value and service excellence. The expanding
research in autoimmune diseases is promising, positioning us to address this
growing need and significantly expand our presence in the high-impact,
late-stage CNS trials market. We're encouraged by this momentum, with this
major contract following shortly after last week's £1.2m agreement for Phase
3 clinical trials in adolescents with Major Depressive Disorder."

 

1. Wang, L., Wang, F.S. & Gershwin, M.E. (2015). Human autoimmune
diseases: a comprehensive update. Journal of Internal Medicine, 278(4),
369-395.

 

Enquiries:

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths                 cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products to advance brain health research and treatment.

The Company offers four core products:

· CANTAB® assessments-providing scientifically validated, highly sensitive,
precise, and objective measures of cognitive function correlated to neural
networks;

· a flexible and proven eCOA platform with an extensive library of
instruments, enabling efficient study setup and scalable data capture;

· rater training services that standardise assessment delivery and scoring
across clinical trials; and,

· quality assurance tools that ensure data integrity by automatically
detecting deviations in administration and scoring, saving time and money.

These products collectively improve clinical trial outcomes, enable early
patient identification, and enhance global efficiency in healthcare and
pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUKONRVUUSRAR